PureTech Health (PureTech Health) Minority Interest : $-5.84 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

PureTech Health's minority interest for the quarter that ended in Dec. 2023 was $-5.84 Mil.

PureTech Health Minority Interest Historical Data

The historical data trend for PureTech Health's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Minority Interest Chart

PureTech Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Minority Interest

Get a 7-Day Free Trial

-17.64

-16.21

-9.37

5.37

-5.84

PureTech Health Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Minority Interest	Get a 7-Day Free Trial															-9.37	-5.73	5.37	-4.78	-5.84

PureTech Health Minority Interest Calculation

PureTech Health (PureTech Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (OTCPK:PTCHF) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

PRTC:USA PRTCl:UK PRTC:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.